Rats bite a Phase III study
Rats bite a Phase III study Long-term preclinical toxicology data have forced Bristol-Myers Squibb Co. to suspend Phase III trials of its lobucavir nucleoside analog to treat chronic hepatitis B and herpes viruses.
The preliminary data from long-term rodent studies of lobucavir indicated a potential drug-related increase in tumors. Bristol-Myers consequently suspended dosing and patient accrual until the data and its implications are fully reviewed.
While a potential link to cancer